Leylagul Kaynar, Muzaffer Keklik, Bulent Eser, Mustafa Cetin, Serhat Celik, Zeynep Tugba Guven, Ali Unal

Retrospective evaluation of patients with primary mediastinal large B-Cell lymphoma: Real life experience

Aim: Primary mediastinal large B-cell lymphoma (PMBCL) is a type of lymphoma that forms approximately 3 % of non-Hodgkin lymphomas that often encounter with mass. The aim of this study was to present the epidemiological characteristics, response rates of the treatment and the survival of PMBCL patients in our single center. Materials and Methods: Patient demographics, treatment regimens, survival rates of PMBCL patients were retrospectively analyzed. Results: There are 15 patients in our study. Most of the patients were female (n:9, 60%). The median age at the time of diagnosis was 35.4. Nine patients applied with a bulky lesion in the mediastinum. Most of the patients have been treated with DA-EPOCH-R (dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine and prednisone with rituximab) (n:13, 87%) and 2 (n:2, 13%) patients have been treated with R-CHOP (doxorubicin, cyclophosphamide, vincristine and prednisone with rituximab) regimens for 6 cycles. Eight patients (53.3%) received involved-field radiotherapy on the mediastinum. After the first-row chemotherapy, total remission rate was 93.3%. Thirteen (87%) of the patients were still in remission and alive. The median follow-up time in our study was 43 months (13 -81). Mean disease-free survival was 67.43 months and overall survival was 72.87 months. The overall and disease-free survival rate was 86.7 % and 80%. Conclusions: In our study, most patients responded to the treatment and are still being followed in remission

PDF

___

1. Swerdlow SH, Campo E, Pileri SA et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-90.
2. Broccoli A, Zinzani PL. The unique biology and treatment of primary mediastinal B-cell lymphoma. Best Pract Res Clin Haematol 2018;31:241-50.
3. Al-Hamadani M, Habermann TM, Cerhan JR et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol 2015;90:790-5.
4. Xu L-M, Li Y-X, Fang H et al. Dosimetric evaluation and treatment outcome of intensity modulated radiation therapy after doxorubicin-based chemotherapy for primary mediastinal large B-cell lymphoma. Int J Radiat Oncol Biol Phys 2013;85:1289-95.
5. Johnson PW, Davies AJ. Primary mediastinal B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2008;2008:349-58.
6. Vassilakopoulos TP, Pangalis GA, Katsigiannis A et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 2012;17:239.
7. Sukswai N, Lyapichev K, Khoury JD et al. Diffuse large B-cell lymphoma variants: an update. Pathology 2020;52:53-67.
8. Wang Y, Wenzl K, Manske MK et al. Amplification of 9p24. 1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer J 2019;9:1-11.
9. Giulino-Roth L. How I treat primary mediastinal B-cell lymphoma. Blood 2018;132:782-90.
10. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-56.
11. Lister T, Crowther D, Sutcliffe S et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6.
12. Shipp M. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Eng J Med 1993;329:987-94.
13. Cheson BD, Fisher RI, Barrington SF et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059.
14. Broccoli A, Casadei B, Stefoni V et al. The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients. BMC Cancer 2017;17:276.
15. Rieger M, Osterborg A, Pettengell R et al. Primary mediastinal B-cell lymphoma treated with CHOPlike chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011;22:664-70.
16. Zinzani PL, Broccoli A, Casadei B et al. The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients. Hematol Oncol 2015;33:145-50.
17. Soumerai JD, Hellmann MD, Feng Y et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma 2014;55:538-43.
18. Martelli M, Ceriani L, Zucca E et al. [18 F] fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol 2014;32:1769-75.
19. Dunleavy K, Pittaluga S, Maeda LS et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:1408-16.
20. Kondo E, Shimizu-Koresawa R, Chihara D et al. Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplantation registry. Br J Haematol 2019;186:e219.
21. Herrera AF, Chen L, Khajavian S et al. Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. Biol Blood Marrow Transplant 2019;25:2383-7.
22. Ansell SM, Minnema MC, Johnson P et al. Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol 2019;37:481.
23. Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood 2015;125:33-9.
24. Kuruvilla J, Pintilie M, Tsang R et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma 2008;49:1329-36.
25. Armand P, Rodig S, Melnichenko V et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol 2019;37:3291-9.
26. Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 2018;131:68-83.
27. Zinzani PL, Ribrag V, Moskowitz CH et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 2017;130:267-70.